CAJ | 학술논문

目的观察2型糖尿病合并原发性高血压(DMEH)患者血清基质金属蛋白酶2(MMP-2)及其组织抑制因子1(TIMP-1)的水平及罗格列酮(RGZ)治疗后的变化. 方法 40例DMEH患者随机分成两组:⑴ DMEH非RGZ治疗组20例(男10例,女10例);(2)DMEH RGZ治疗组20例(男8例,女12例).采用酶联免疫吸附法测定MMP-2、TIMP-1及实验室相关指标,观察RGZ治疗前后MMP-2、 TIMP-1水平变化及与非RGZ治疗组之间变化的差别. 结果应用RGZ治疗组治疗16周后的血清MMP-2、TIMP-1水平分别为(37.9±3.9)μg/L和(410.0±80.9)μg/L,MMP-2水平较治疗前(27.5±4.3)明显升高(P＜0.05);而TIMP-1水平较治疗前(468.1±100.6)明显降低(P＜0.05). 结论 RGZ治疗除能改善血糖及血压外,可升高MMP-2和降低TIMP-1水平.
목적 관찰2형당뇨병합병원발성고혈압(DMEH)환자혈청기질금속단백매2(MMP-2)급기조직억제인자1(TIMP-1)적수평급라격렬동(RGZ)치료후적변화. 방법 40례DMEH환자수궤분성량조:⑴ DMEH비RGZ치료조20례(남10례,녀10례);(2)DMEH RGZ치료조20례(남8례,녀12례).채용매련면역흡부법측정MMP-2、TIMP-1급실험실상관지표,관찰RGZ치료전후MMP-2、 TIMP-1수평변화급여비RGZ치료조지간변화적차별. 결과 응용RGZ치료조치료16주후적혈청MMP-2、TIMP-1수평분별위(37.9±3.9)μg/L화(410.0±80.9)μg/L,MMP-2수평교치료전(27.5±4.3)명현승고(P＜0.05);이TIMP-1수평교치료전(468.1±100.6)명현강저(P＜0.05). 결론 RGZ치료제능개선혈당급혈압외,가승고MMP-2화강저TIMP-1수평.
Objective To observe the effect of rosiglitazone on MMP-2 and TIMP-1 in the patients with diabetic hypertension.Methods 40 diabetic patients with essential hypertension(DMEH)were divided into 2 groups:(1)group A(n=20)without rosiglitazone treatment;(2)group B(n=20)undergoing rosiglitazone treatment.ELISA method was adopted to determine the levels of MMP-2 and TIMP-1,and the differences in MMP-2 and TIMP-1 between pre-and post-use of rosiglitazone were observed.Results At 16 weeks of the treatment by rosiglitazone,the level of MMP-2 was higher after treatment than before treatment [(37.9±3.9)vs(27.5±4.3)μg/L,P<0.05],and the level of TIMP-1 was lower after treatment than before treatment[(410±81)vs(468±101)μg/L,P<0.01].Conclusions Rosiglitazone not only improves blood sugar and blood pressure,but also raises the level of MMP-2 and reduces the level of TIMP-1